Heidelberg Pharma AG, a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announced the presentation of new clinical data from its ongoing Phase I/IIa clinical study evaluating its lead Amanitin-based ADC candidate, HDP-101 (INN: pamlectabart tismanitin), at the 16th Annual World ADC Congress, taking place in San Diego, California, from 3 to 6 November 2025.
– Objective responses and promising anti-tumor activity observed in several patients across multiple cohorts in the ongoing Phase I/IIa clinical trial
– Data reinforces the therapeutic potential and safety profile of HDP-101 in relapsed or refractory multiple myeloma.
– R&D Webinar to be hosted on 11 November 2025 at 05:00 pm CET (08:00 am PST)